Histogenics Corp. (NASDAQ:HSGX)’s share price dropped 8.7% during mid-day trading on Wednesday . The stock traded as low as $2.84 and last traded at $3.37, with a volume of 232,524 shares traded. The stock had previously closed at $3.69.

HSGX has been the topic of several research analyst reports. Canaccord Genuity restated a “buy” rating on shares of Histogenics Corp. in a research note on Thursday, May 12th. BTIG Research upgraded Histogenics Corp. from a “neutral” rating to a “buy” rating and set a $3.50 price objective on the stock in a research note on Thursday, August 11th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $9.75.

The company’s market cap is $43.93 million. The stock’s 50 day moving average price is $1.99 and its 200-day moving average price is $2.19.

Histogenics Corp. (NASDAQ:HSGX) last posted its earnings results on Thursday, August 11th. The company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.01. During the same period in the previous year, the business posted ($0.58) earnings per share. On average, equities analysts anticipate that Histogenics Corp. will post ($2.09) EPS for the current fiscal year.

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.